semaglutide phase 1 Novo Nordisk announced headline results from STEP UP, a IIIb trial investigating subcutaneous 7.2 mg for obesity Pivotal Results for Semaglutide in
Description
2021-I2M-1-028)
Side effects to monitor for include muscle pain or weakness, high blood pressure, thin skin, impaired wound healing, and altered mental status
doi:10.1161/01.RES.0000090361.45027.5B
Eggleton JS, Jialal I
